14 July 2020
The Hepatitis C Assessment Through to Treatment Trial (HepCATT) investigated a multi-part intervention to increase the identification and treatment of patients with hepatitis C in primary care. We are sharing the learning from this trial to support the implementation of the NHS England Hepatitis C Virus Elimination Initiative in Primary Care.
Researchers from the University of Bristol’s NIHR Health Protection Research Unit in Behavioural Science and Evaluation and Centre for Academic Primary Care investigated an algorithm to identify patients at risk of HCV in primary care through the HepCATT (Hepatitis C Assessment Through to Treatment) randomised controlled trial. The intervention was found to be effective, acceptable to staff and highly cost-effective for the NHS.
When conducting HepCATT we learnt some useful lessons about how to implement the intervention, which we hope will be helpful to NHS England and GP practice staff taking part in the NHS England programme.
Find out more and watch the video explainer.
Further information
About the NIHR
The National Institute for Health Research (NIHR) is the nation’s largest funder of health and care research. The NIHR:
- funds, supports and delivers high quality research that benefits the NHS, public health and social care
- engages and involves patients, carers and the public in order to improve the reach, quality and impact of research
- attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future
- invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services
- partners with other public funders, charities and industry to maximise the value of research to patients and the economy.
The NIHR was established in 2006 to improve the health and wealth of the nation through research, and is funded by the Department of Health and Social Care. In addition to its national role, the NIHR supports applied health research for the direct and primary benefit of people in low- and middle-income countries, using UK aid from the UK government.